Clinical trial
Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle…
NCT00004408 · Mast Therapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT00004408 |
|---|---|
| Title | Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease |
| Lead sponsor | Mast Therapeutics, Inc., Industry |
| Collaborators | CytRx Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sickle Cell Anemia |
| Intervention type | Drug |
| Interventions | poloxamer 188 |
| Enrollment | 300 |
| Start date | Nov 1, 1997 |
| Completion | Nov 1, 1999 |
| First posted | Oct 19, 1999 |
| Last update posted | Mar 6, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: